MedTrace Logo

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)

NCT03278509 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2024-03-05

No results posted yet for this study

Summary

Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study is to determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite of death of any cause or new myocardial infarction..

Conditions

  • Acute Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • ST Elevation Myocardial Infarction

Interventions

DRUG

Metoprolol Succinate

Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).

DRUG

Bisoprolol

Please see the section above.

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Tomas Jernberg, MD PhD · Karolinska Institutet

  • Bertil Lindahl, MD PhD · Uppsala, Clinical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2023-11-16
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03278509 on ClinicalTrials.gov